- Home
- Argentina Menopause Drugs Market
Argentina Menopause Drugs Market - Industry Trends and Forecast to 2029
- Published Date: January, 2022 | Report ID: CLS-10 | No of pages: 150 | Format:
Argentina Menopause Drugs Market, By Stages (Postmenopause, Perimenopause and Menopause), Type (Non-Hormonal Therapy and Hormonal Therapy), Menopause Symptoms (Vasomotor Symptoms, Atrophic Vaginitis, Dyspareunia, Osteoporosis, Joint Pain, Depression, Weight Gain and Others), Dosage Form (Tablet, Cream, Patch/Film, Rings, Gel, Injection Shot, Spray and Others), Route of Administration (Oral, Parenteral, Transdermal, Vaginal and Others), End User (Hospitals, Clinic Home Healthcare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (Argentina) Industry Trends and Forecast to 2029.
Market Definition:
The term menopause means a specific time period, for 12 months after a woman's last period. The years leading up to the point, when women may have changes in the menstrual cycles. During menopause, a woman's body makes less of the hormones estrogen and progesterone. The lower hormone levels, lead to onset of menopause symptoms such as hot flashes, vasomotor symptoms, atrophic vaginitis, dyspareunia, osteoporosis, joint pain, depression and weight gain.
Some women choose to treat their menopause symptoms with hormonal and non-hormonal therapies. The hormonal therapy medications are estrogen, progesterone, a cocktail of estrogen with progesterone drugs and medroxyprogesterone acetate. The progestin-only medicines are taken with estrogen-only medicines, to lower the chance of getting endometrial cancer in women who still have their uterus.
Argentina has one of the largest populations of the elderly people in Latin America. The ageing population in Argentina are due to rise in fertility and mortality rates. The shift causes an increase in demand for long-term care for older people, particularly those requiring help with activities of daily living.
Argentina menopause drugs market is projected to register a substantial CAGR of 4.6% in the forecast period of 2022 to 2029 The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029
Some of the major factors contributing to the growth of the Argentina menopause drugs market are:
• The rise in collaboration, with the research and development (R&D) of the pharmaceutical companies for the production of menopause drugs
• The rise in product approvals of dietary supplements
TABLE OF CONTENT
| 1 INTRODUCTION 14 1.1 OBJECTIVES OF THE STUDY 14 1.2 MARKET DEFINITION 14 1.3 OVERVIEW OF ARGENTINA MENOPAUSE DRUGSMARKET 14 1.4 CURRENCY AND PRICING 16 1.5 LIMITATIONS 17 1.6 MARKETS COVERED 17 2 ARGENTINA MENOPAUSE DRUGSMARKET: SEGMENTATION 20 2.1 MARKETS COVERED 20 2.2 COUNTRY SCOPE 21 2.3 YEARS CONSIDERED FOR THE STUDY 21 2.4 DBMR TRIPOD DATA VALIDATION MODEL 22 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 25 2.6 MULTIVARIATE MODELLING 26 2.7 CAUSE SEGMENT LIFELINE CURVE 26 2.8 DBMR MARKET POSITION GRID 27 2.9 VENDOR SHARE ANALYSIS 29 2.10 MARKET END USER COVERAGE GRID 30 2.11 SECONDARY SOURCES 31 3 EXECUTIVE SUMMARY 32 4 PREMIUM INSIGHTS 35 4.1 PORTERS FIVE FORCES 36 4.2 PESTEL ANALYSIS 37 5 EPIDEMIOLOGY 38 6 ARGENTINA MENOPAUSE DRUGS MARKET: REGULATIONS 39 6.1 ARGENTINA 39 6.2 COUNTRY SPECIFIC REQUIREMENTS 40 7 PIPELINE ANALYSIS, ARGENTINA MENOPAUSE DRUGS MARKET 41 8 SUMMARY WRITE UP (ARGENTINA) 42 8.1 OVERVIEW 42 9 MARKET OVERVIEW 43 9.1 DRIVERS 45 9.1.1 RISE IN RESEARCH AND DEVELOPMENT 45 9.1.2 RISE IN AGEING POPULATION AMONG WOMEN IN ARGENTINA 45 9.1.3 RISE IN PRODUCT APPROVAL 46 9.1.4 RISE IN GOVERNMENT INITIATIVES AND ORGANIZATIONS 46 9.1.5 REIMBURSEMENT FOR MENOPAUSE TREATMENT 47 9.2 RESTRAINTS 47 9.2.1 RISE IN COST OF MENOPAUSE DRUGS AND HORMONAL THERAPY 47 9.2.2 COMPLEXITY IN MENOPAUSE 47 9.2.3 RISE IN PRODUCT RECALL 48 9.2.4 LACK OF AWARENESS ABOUT MENOPAUSE 48 9.3 OPPORTUNITIES 48 9.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 48 9.3.2 RISE IN HEALTHCARE EXPENDITURE 49 9.3.3 USE OF DIETARY SUPPLEMENTS 49 9.4 CHALLENGES 50 9.4.1 SIDE EFFECTS CAUSED DUE TO DRUGS TAKEN FOR MENOPAUSE TREATMENT 50 9.4.2 STRINGENT REGULATIONS 50 10 IMPACT OF COVID-19 ON ARGENTINA MENOPAUSE DRUGS MARKET 51 10.1 IMPACT ON PRICE 51 10.2 IMPACT ON DEMAND 51 10.3 IMPACT ON SUPPLY CHAIN 52 10.4 STRATEGIC DECISIONS BY MANUFACTURERS 52 10.5 CONCLUSION 53 11 ARGENTINA MENOPAUSE DRUGS MARKET, BY STAGES 54 11.1 OVERVIEW 55 11.2 POSTMENOPAUSE 58 11.3 PERIMENOPAUSE 58 11.4 MENOPAUSE 58 12 ARGENTINA MENOPAUSE DRUGS MARKET, BY TYPE 59 12.1 OVERVIEW 60 12.2 NON-HORMONAL THERAPY 63 12.2.1 MEDICATION 63 12.2.1.1 PAROXETINE 64 12.2.1.2 ANTI-DEPRESSANTS 64 12.2.1.3 GABAPENTIN 64 12.2.1.4 CLONIDINE 64 12.2.1.5 OSPEMIFENE 64 12.2.1.6 OTHERS 64 12.2.2 SUPPLEMENTS 64 12.2.2.1 HERBAL SUPPLEMENTS 65 12.2.2.1.1 GINSENG 65 12.2.2.1.2 ASHWAGANDHA 65 12.2.2.1.3 OTHERS 65 12.2.2.2 VITAMIN D 65 12.2.2.3 OTHERS 65 12.3 HORMONAL THERAPY 66 12.3.1 ESTROGEN 66 12.3.1.1 17 B- ESTRADIOL 67 12.3.1.2 CONJUGATED ESTROGEN 67 12.3.1.3 ESTRADIOL HEMIHYDRATE 67 12.3.1.4 ESTERIFIED ESTROGEN 67 12.3.1.5 ESTERIFIED ACETATE 67 12.3.1.6 ESTROPIPATE 67 12.3.1.7 OTHERS 67 12.3.2 COMBINED ESTROGEN & PROGESTOGEN DRUGS 67 12.3.2.1 17 B- ESTRADIOL (E) + NORETHINODRONE ACETATE (P) 68 12.3.2.2 CONJUGATED ESTROGENS (E) + MEDROXYPROGESTERONE ACETATE (P) 68 12.3.2.3 ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) 68 12.3.2.4 OTHERS 68 12.3.3 MEDROXYPROGESTERONE ACETATE 68 13 ARGENTINA MENOPAUSE DRUGS MARKET, BY MENOPAUSE SYMPTOMS 69 13.1 OVERVIEW 70 13.2 VASOMOTOR SYMPTOMS 73 13.2.1 HORMONAL THERAPY 73 13.2.2 NON- HORMONAL THERAPY 73 13.3 ATROPHIC VAGINITIS 73 13.3.1 HORMONAL THERAPY 74 13.3.2 NON- HORMONAL THERAPY 74 13.4 DYSPAREUNIA 74 13.4.1 NON- HORMONAL THERAPY 74 13.4.2 HORMONAL THERAPY 74 13.5 OSTEOPOROSIS 74 13.5.1 NON- HORMONAL THERAPY 75 13.5.2 HORMONAL THERAPY 75 13.6 JOINT PAIN 75 13.6.1 NON- HORMONAL THERAPY 76 13.6.2 HORMONAL THERAPY 76 13.7 DEPRESSION 76 13.7.1 NON- HORMONAL THERAPY 77 13.7.2 HORMONAL THERAPY 77 13.8 WEIGHT GAIN 77 13.8.1 HORMONAL THERAPY 78 13.8.2 NON- HORMONAL THERAPY 78 13.9 OTHERS 78 14 ARGENTINA MENOPAUSE DRUGS MARKET, BY DOSAGE FORM 79 14.1 OVERVIEW 80 14.2 TABLET 83 14.3 CREAM 83 14.4 PATCH/FILM 83 14.5 RINGS 83 14.6 GEL 84 14.7 INJECTION SHOT 84 14.8 SPRAY 84 14.9 OTHERS 85 15 ARGENTINA MENOPAUSE DRUGS MARKET, BY ROUTE OF ADMINISTRATION 86 15.1 OVERVIEW 87 15.2 ORAL 90 15.3 PARENTERAL 90 15.3.1 INTRAVENOUS 90 15.3.2 SUBCUTANEOUS 90 15.3.3 OTHERS 91 15.4 TRANSDERMAL 91 15.5 VAGINAL 91 15.6 OTHERS 91 16 ARGENTINA MENOPAUSE DRUGS MARKET, BY END USER 92 16.1 OVERVIEW 93 16.2 HOSPITAL 96 16.3 CLINICS 96 16.4 HOME HEALTHCARE 96 16.5 OTHERS 97 17 ARGENTINA MENOPAUSE DRUGS MARKET, BY DISTRIBUTION CHANNEL 98 17.1 OVERVIEW 99 17.2 RETAIL PHARMACY 102 17.3 HOSPITAL PHARMACY 102 17.4 ONLINE PHARMACY 102 18 ARGENTINA MENOPAUSE DRUGS MARKET: COMPANY LANDSCAPE 103 18.1 COMPANY SHARE ANALYSIS: ARGENTINA 103 19 SWOT ANALYSIS 104 20 COMPANY PROFILE 105 20.1 PFIZER INC. 105 20.1.1 COMPANY SNAPSHOT 105 20.1.2 REVENUE ANALYSIS 105 20.1.3 PRODUCT PORTFOLIO 106 20.1.4 RECENT DEVELOPMENTS 106 20.2 BAYER AG 108 20.2.1 COMPANY SNAPSHOT 108 20.2.2 REVENUE ANALYSIS 108 20.2.3 PRODUCT PORTFOLIO 109 20.2.4 RECENT DEVELOPMENTS 109 20.3 NOVARTIS AG 110 20.3.1 COMPANY SNAPSHOT 110 20.3.2 REVENUE ANALYSIS 110 20.3.3 PRODUCT PORTFOLIO 111 20.3.4 RECENT DEVELOPMENTS 111 20.4 LABORATORIOS BAGO S.A. 112 20.4.1 COMPANY SNAPSHOT 112 20.4.2 PRODUCT PORTFOLIO 112 20.4.3 RECENT DEVELOPMENTS 112 20.5 GLAXOSMITHKLINE PLC(2021) 113 20.5.1 COMPANY SNAPSHOT 113 20.5.2 REVENUE ANALYSIS 113 20.5.3 PRODUCT PORTFOLIO 114 20.5.4 RECENT DEVELOPMENT 114 20.6 TEVA PHARMACEUTICAL INDUSTRIES LTD. 115 20.6.1 COMPANY SNAPSHOT 115 20.6.2 REVENUE ANALYSIS 115 20.6.3 PRODUCT PORTFOLIO 116 20.6.4 RECENT DEVELOPMENTS 116 20.6.4.1 PARTNERSHIP 116 20.6.4.2 PRODUCT LAUNCH 117 20.7 NOVO NORDISK A/S 118 20.7.1 COMPANY SNAPSHOT 118 20.7.2 REVENUE ANALYSIS 118 20.7.3 PRODUCT PORTFOLIO 119 20.7.4 RECENT DEVELOPMENT 119 20.8 ABBVIE INC. 120 20.8.1 COMPANY SNAPSHOT 120 20.8.2 REVENUE ANALYSIS 120 20.8.3 PRODUCT PORTFOLIO 121 20.8.4 RECENT DEVELOPMENTS 121 20.9 ABBOTT 122 20.9.1 COMPANY SNAPSHOT 122 20.9.2 REVENUE ANALYSIS 122 20.9.3 PRODUCT PORTFOLIO 123 20.9.4 RECENT DEVELOPMENT 123 20.10 ACHE LABORATÓRIOS FARMACÊUTICOS S/A 124 20.10.1 COMPANY SNAPSHOT 124 20.10.2 REVENUE ANALYSIS 124 20.10.3 PRODUCT PORTFOLIO 125 20.10.4 RECENT DEVELOPMENTS 125 20.11 GADOR S.A. 126 20.11.1 COMPANY SNAPSHOT 126 20.11.2 PRODUCT PORTFOLIO 126 20.11.3 RECENT DEVELOPMENTS 126 20.12 LABORATORIOS BERNABO S.A. 127 20.12.1 COMPANY SNAPSHOT 127 20.12.2 PRODUCT PORTFOLIO 127 20.12.3 RECENT DEVELOPMENTS 127 20.13 LABORATORIO ELEA PHOENIX S.A. 128 20.13.1 COMPANY SNAPSHOT 128 20.13.2 PRODUCT PORTFOLIO 128 20.13.3 RECENT DEVELOPMENT 128 20.13.3.1 PRODUCT LAUNCH 128 20.14 QUIMICA MONTPELLIER S.A. 129 20.14.1 COMPANY SNAPSHOT 129 20.14.2 PRODUCT PORTFOLIO 129 20.14.3 RECENT DEVELOPMENTS 129 20.15 ROEMMERS SAICF 130 20.15.1 COMPANY SNAPSHOT 130 20.15.2 PRODUCT PORTFOLIO 130 20.15.3 RECENT DEVELOPMENTS 130 20.16 TEMIS LOSLATO 131 20.16.1 COMPANY SNAPSHOT 131 20.16.2 PRODUCT PORTFOLIO 131 20.16.3 RECENT DEVELOPMENTS 131 21 QUESTIONNAIRE 132 22 RELATED REPORTS 136 |
Segmentation
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.